Trial intelligence / Profile preview

Gaviscon Double Action Tablets for reflux disease symptoms

2012-002188-84Phase 3Completed

Sponsor
Reckitt
Start
Jun 2012
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of Gaviscon Double Action in gastroesophageal reflux disease (GERD), sponsored by Reckitt. Started Jun 2012; status: completed.

02

Drugs

Gaviscon Double Action
03

Conditions

gastroesophageal reflux disease (GERD)

Beyond the preview

Go deeper on 2012-002188-84.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-002188-84.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call